Actuate Therapeutics (NASDAQ:ACTU) Now Covered by HC Wainwright

Investment analysts at HC Wainwright initiated coverage on shares of Actuate Therapeutics (NASDAQ:ACTU) in a research note issued on Monday. The brokerage set a “buy” rating and a $20.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 175.86% from the company’s previous close.

Actuate Therapeutics Price Performance

Shares of NASDAQ:ACTU opened at $7.25 on Monday. Actuate Therapeutics has a 12-month low of $5.51 and a 12-month high of $11.73. The stock’s 50-day moving average price is $8.18 and its two-hundred day moving average price is $8.08.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Sigma Planning Corp acquired a new stake in shares of Actuate Therapeutics in the 4th quarter valued at about $128,000. Northwestern University acquired a new position in Actuate Therapeutics during the 3rd quarter valued at about $207,000. Freestone Capital Holdings LLC bought a new position in Actuate Therapeutics in the 4th quarter worth approximately $80,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Actuate Therapeutics during the fourth quarter valued at $84,000. Finally, BIOS Capital Management LP bought a new stake in shares of Actuate Therapeutics during the 4th quarter worth about $78,753,000.

About Actuate Therapeutics

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.